

Global Cell Therapy Market Forecast 2022-2030

Market Report | 2022-10-24 | 228 pages | Inkwood Research

AVAILABLE LICENSES:

- Single User Price \$2500.00
- Global Site License \$3000.00
- \$4500.00

Report description:

KEY FINDINGS

The global cell therapy market is projected to register a CAGR of 14.46% during the forecast period, 2022-2030. The market growth is accredited to the increasing prevalence of chronic disease, thriving regenerative medicine, and rising cellular therapy clinical trials.

MARKET INSIGHTS

Cell therapy has a vast range of applications in offering diagnostic/prognostic information during clinical research related to several infectious diseases, cancer, and HIV/AIDS. Also, several factors like the growing population, climate change, and the growing contact between animals and humans have raised the threat of virus outbreaks. Cell therapy replaces dysfunctional or diseased cells with healthy functioning ones. The cells majorly used for such advanced therapies are stem cells, given their ability to differentiate into specific cells needed for repairing defective cells.

Further, cell therapy has applications in the development of regenerative medicine. Additionally, cells like bone marrow and blood cells, embryonic stem cells, adult stem cells, and solid & immature cells are used in cell therapy procedures. Such factors drive the global cell therapy market growth. However, the growing skills gap restricts market growth.

REGIONAL INSIGHTS

The global cell therapy market's geographical segmentation includes the assessment of Asia-Pacific, Europe, North America, and Rest of World. North America is the largest revenue-generating region in the global market, supplemented by the presence of key players, advanced healthcare infrastructure, robust reimbursement policies, extensive research and development, etc.

COMPETITIVE INSIGHTS

Some of the eminent companies operating in the market include Bristol Myers Squibb Company, Gilead Sciences Inc, Cells for Cells SA, JCR Pharmaceuticals Co Ltd, Anterogen Co Ltd, etc.

Our report offerings include:

- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Table of Contents:

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY
 - 1.1. STUDY OBJECTIVES
 - 1.2. SCOPE OF STUDY
 - 1.3. METHODOLOGY
 - 1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
 - 2.1. MARKET SIZE & ESTIMATES
 - 2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
 - 3.1. KEY DRIVERS
 - 3.1.1. INCREASING CELLULAR THERAPY CLINICAL TRIALS
 - 3.1.2. GROWTH OF REGENERATIVE MEDICINE
 - 3.1.3. HIGH PREVALENCE OF CHRONIC DISEASES
 - 3.2. KEY RESTRAINTS
 - 3.2.1. INCREASING SKILLS GAP
 - 3.2.2. HIGH COSTS
4. KEY ANALYTICS
 - 4.1. IMPACT OF COVID-19 ON CELL THERAPY MARKET
 - 4.2. KEY MARKET TRENDS
 - 4.3. PORTER'S FIVE FORCES ANALYSIS
 - 4.3.1. BUYERS POWER
 - 4.3.2. SUPPLIERS POWER
 - 4.3.3. SUBSTITUTION
 - 4.3.4. NEW ENTRANTS
 - 4.3.5. INDUSTRY RIVALRY
 - 4.4. REGULATORY FRAMEWORK
 - 4.5. OPPORTUNITY MATRIX
 - 4.6. VENDOR LANDSCAPE
5. MARKET BY CELL TYPE
 - 5.1. STEM CELL
 - 5.1.1. BONE MARROW
 - 5.1.2. BLOOD
 - 5.1.3. UMBILICAL CORD-DERIVED STEM CELL
 - 5.1.4. ADIPOSE-DERIVED STEM CELL
 - 5.1.5. OTHERS
 - 5.2. NON-STEM CELL
6. MARKET BY THERAPY TYPE
 - 6.1. AUTOLOGOUS
 - 6.2. ALLOGENEIC

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7. MARKET BY THERAPEUTIC APPLICATION

7.1. MALIGNANCIES

7.2. MUSCULOSKELETAL DISORDERS

7.3. AUTOIMMUNE DISORDERS

7.4. DERMATOLOGY

7.5. OTHER APPLICATIONS

8. MARKET BY END-USER

8.1. HOSPITALS & CLINICS

8.2. ACADEMIC & RESEARCH INSTITUTES

9. GEOGRAPHICAL ANALYSIS

9.1. NORTH AMERICA

9.1.1. MARKET SIZE & ESTIMATES

9.1.2. KEY DRIVERS

9.1.3. KEY CHALLENGES

9.1.4. KEY PLAYERS

9.1.5. COUNTRY ANALYSIS

9.1.5.1. UNITED STATES

9.1.5.2. CANADA

9.2. EUROPE

9.2.1. MARKET SIZE & ESTIMATES

9.2.2. KEY DRIVERS

9.2.3. KEY CHALLENGES

9.2.4. KEY PLAYERS

9.2.5. COUNTRY ANALYSIS

9.2.5.1. UNITED KINGDOM

9.2.5.2. GERMANY

9.2.5.3. FRANCE

9.2.5.4. ITALY

9.2.5.5. SPAIN

9.2.5.6. BELGIUM

9.2.5.7. POLAND

9.2.5.8. REST OF EUROPE

9.3. ASIA-PACIFIC

9.3.1. MARKET SIZE & ESTIMATES

9.3.2. KEY DRIVERS

9.3.3. KEY CHALLENGES

9.3.4. KEY PLAYERS

9.3.5. COUNTRY ANALYSIS

9.3.5.1. CHINA

9.3.5.2. JAPAN

9.3.5.3. INDIA

9.3.5.4. SOUTH KOREA

9.3.5.5. THAILAND

9.3.5.6. SINGAPORE

9.3.5.7. AUSTRALIA & NEW ZEALAND

9.3.5.8. REST OF ASIA-PACIFIC

9.4. REST OF WORLD

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.4.1. MARKET SIZE & ESTIMATES
- 9.4.2. KEY DRIVERS
- 9.4.3. KEY CHALLENGES
- 9.4.4. KEY PLAYERS
- 9.4.5. REGIONAL ANALYSIS
 - 9.4.5.1. LATIN AMERICA
 - 9.4.5.2. MIDDLE EAST & AFRICA
- 10. COMPETITIVE LANDSCAPE
 - 10.1. KEY STRATEGIC DEVELOPMENTS
 - 10.1.1. MERGERS & ACQUISITIONS
 - 10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
 - 10.1.3. PARTNERSHIPS & AGREEMENTS
 - 10.1.4. BUSINESS EXPANSIONS
 - 10.2. COMPANY PROFILES
 - 10.2.1. ANTEROGEN CO LTD
 - 10.2.2. BRISTOL MYERS SQUIBB COMPANY
 - 10.2.3. CELLS FOR CELLS SA
 - 10.2.4. GILEAD SCIENCES INC
 - 10.2.5. JCR PHARMACEUTICALS CO LTD
 - 10.2.6. KOLON TISSUEGENE INC
 - 10.2.7. MEDIPOST CO LTD
 - 10.2.8. MESOBLAST LIMITED
 - 10.2.9. NUVASIVE INC
 - 10.2.10. SMITH & NEPHEW PLC
 - 10.2.11. STEMEDICA CELL TECHNOLOGIES INC
 - 10.2.12. VERICEL CORPORATION

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Cell Therapy Market Forecast 2022-2030

Market Report | 2022-10-24 | 228 pages | Inkwood Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$2500.00
	Global Site License	\$3000.00
		\$4500.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-03"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com